2 fractions will be delivered to treat low- or intermediate- risk prostate cancer

Pencil Beam Proton Therapy Treatment Machine

This study focused on the prostate cancer, which only occur in male.

Oi Lei Wong, Ph.D.

Darren Ming Chun Poon, Dr.

Group 1 Definitive Reirradiation Phase II

* Patients w/history of intracranial or spinal (extradural, intradural, and/or intramedullary) CNS tumors for which radiation therapy was prev. delivered either to gross disease or in the postoperative setting
* Min. 6 month interval b/w RT courses
* Overlap of prior RT field (50% IDL)
* Subgroup analysis: receipt of surgery for recurrence/second IC tumor; concurrent ST; tumor histology

Group 2 CNS Reirradiation Registry

* Patients for whom a repeat course of RT to the CNS is indicated for recurrent disease or secondary primary
* Postop or intact setting
* Min. 6 month interval b/w RT courses
* Overlap of prior RT field (50% IDL)
* Histologically/clinically documented recurrent CNS tumor (benign or malignant)
* Glioblastoma (histologic or molecular including IDH wildtype)
* Astrocytoma (molecular IDH1 mutant)
* Oligodendroglioma (molecular 1p19q co deleted)
* Meningioma
* Ependymoma
* Chordoma/chondrosarcoma

Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies

Pencil Beam Scanning Proton Therapy

Group 1 Full Dose Reirradiation Phase II

* Patients w/history of HNC for which RT was delivered definitively, now with recurrence to h/n amenable to full dose reRT
* Gross unresected disease or PORT 2/2 RF
* Received at least 40 Gy overlapping w/new target region
* Min. 6 month interval b/w RT courses
* Overlap of prior RT field (50% IDL)
* Subgroup analysis: surgery, HPV status, concurrent ST

Group 2 Early (\<6months for prior RT) Palliative H/N ReRT Phase I

* Patients w/history of HNC for which RT was delivered definitively/adjuvant setting, now with biopsy proven recurrence to h/n with indication for palliative RT
* At least 30 Gy prior RT overlapping with new treatment volume
* \<6 month interval between RT courses

Group 3 Head/Neck ReRT Registry

* Patients w/history of HNC for which RT was delivered now with recurrence/secondary primary requiring reRT
* Postop or definitive
* Prior RT dose at least 30 Gy overlapping w/new treatment volume
* Min.6 month interval b/w RT courses

Group 1 Partial Breast Reirradiation (Phase II)

* Patients with a history of breast cancer s/p BCT, now with small (≤3cm), unicentric, ipsilateral breast cancer recurrence receiving repeat BCT
* Node negative
* Negative margins
* No LVI
* Lumpectomy cavity:whole breast \<30%
* Minimum 1 year interval between RT courses

Group 2: Regional LN and Breast/CW ReRT (Phase II)

* Patients with a history of breast cancer s/p RT , now with recurrence or new primary with indication for reirradiation to the breast/chest wall and regional LN
* Minimum 1 year interval between RT courses
* Negative metastatic workup (PET/CT or CT C/A/P + bone scan)
* Excludes concurrent chemotherapy

Group 3: Breast Reirradiation Registry

* Patients with a history of breast cancer s/p RT , now with recurrence or new primary breast cancer with indication for reirradiation
* Some overlaps of dose with prior RT course
* Negative metastatic workup (PET/CT or CT C/A/P + bone scan)
* Excludes concurrent chemotherapy

Group 1: Definitive Reirradiation for Locally Advanced Disease

* Single arm, prospective, phase II study
* Patients with a history of lung cancer s/p definitive RT , now with local recurrence of new primary centrally located and w/I 50% IDL of prior RT field
* Definitive reRT concurrent systemic therapy
* Adequate pulmonary function defined as an FEV1 of \>35% (with or without bronchodilator) within 90 days prior to registration
* Minimum 6 month interval between RT courses
* Negative metastatic workup

Group 2: Thoracic Registry Study

* Registry design
* Patients with histologically confirmed thoracic malignancy (NSCLC, SCLC , mesothelioma, thymoma, carcinoid, intrathoracic sarcoma) with prior thoracic RT
* Minimum 3 month interval between RT courses
* Negative metastatic workup

Group 1 Esophagus \& GEJ Reirradiation Phase II

* Patients w/history of E/GEJ cancer s/p RT, now w/recurrent/new primary nonmetastatic E/GEJ cancer for which salvage RT is recommended
* Negative metastatic workup

Group 2 Liver Reirradiation Phase II

* Patients w/history of HCC, cholangiocarcinoma or liver mets (any histology), s/p prior EBRT, now with in field recurrence/new primary/met, for which definitive reRT is recommended
* CTP A or B7
* Excl. prev. Y 90/radioembolization
* Allow prior TACE
* Overlap w/50% IDL prior RT
* Adequate bone marrow function

Group 3 Lower GI Reirradiation Phase II

* Patients w/history of rectal/anal cancer s/p RT now w/recurrent/new primary nonmetastatic rectal/anal cancer for whom salvage RT is recommended +/ chemotherapy
* Negative metastatic workup (PET/CT or CT C/A/P)

Group 4 GI Reirradiation Registry

•Patients w/histologically document recurrent or new GI malignancy with prior history of RT w/overlap of current RT volume by the 50% IDL

Group 1 Locally recurrent prostate cancer w/in prev. radiation field Phase II

* Patients w/recurrent prostate adenocarcinoma w/in prev. irradiated field w/indication for repeat course of radiation
* Min. 1 year interval b/w RT courses
* Prostate gland or recurrent tumor \<100 cc or 6 cm in largest dimension
* No persistent grade 2+ toxicity from prior radiation
* Negative metastatic workup (bone scan, CT scan or PSMA/axumin scan

Group 2 Regional prostate cancer recurrence adjacent to the previous field Phase II

* Patients w/recurrent prostate adenocarcinoma beyond prior RT field (outside 50% IDL) but w/in pelvis)
* Min.1 year interval b/w RT courses (EBRT or brachy)
* No persistent grade 2+ toxicity from prior radiation

Group 3 Prostate Reirradiation Registry

* Patients w/recurrent prostate adenocarcinoma (prostate gland, postop bed, or pelvi c LN) who require RT to the prostate or pelvis in the setting of prior pelvis RT
* No DM
* Concurrent chemotherapy excl.

Group 1: Locally recurrent gynecological cancer within previous field

* Single arm, prospective, phase II study design
* Patients with history of gyn cancer for which definitive or adjuvant/salvage PORT was given, now with recurrence within 50% IDL recommended for radiotherapy
* At least 1 year between RT courses
* No persistent grade 3+ toxicity from prior RT
* Concurrent chemotherapy excluded
* Uncontrolled or widely metastatic disease
* Life expectancy \>6 months

* Registry design
* Any cancer patient for whom RT is indicated in the setting of prior RT and do not meet eligibility criteria for other cohorts
* Overlap of 50% IDL of current treatment volume with prior RT field

Isabelle Choi, MD

Part A: OSE-279 100mg

Part A: OSE-279 300mg

Part A: OSE-279 600mg

OSE-279: OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine

Part B: OSE-279 600 mg and OSE2101

Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive

OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine

Part C: OSE-279 600 mg - HLA-A2 positif

Part C: OSE-279 600 mg - HLA-A2 negative

Radiation delivered as per standard institutional approaches

Daily use of pantoprazole magnesium, rabeprazole or lansoprazole

The intervention uses a proton pump inhibitor as a preventative measure

Experimental (Health Canada Approved Proton Pump Inhibitors)

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

레어노트에 환자 모임 등록

회원 모집 중

환자 모임 설문 2254% 진행

당원병 환우들의 건강하고 행복한 삶을 위해 노력합니다. 차별 없이 하고 싶은 꿈을 펼칠 수 있는 삶을 위해 지원합니다.

<dl class="v3-editor-content-dictionary">
<dt>당원병(글리코젠축적병)이란</dt>
<dd>당질 대사에 관계있는 효소의 결손에 의하여 간, 신, 심, 근육 등의 조직에 대량의 글리코겐(당원)이 축적하는 질환군을 말합니다. 폰기에르케병(1형), 안데르센병(4형), 맥아들병(5형) 등 결핍된 효소의 종류에 따라 세부 유형이 달라집니다. </dd>
<dd> </dd>
<dd><a href="rarenote://MedicalNewsDetail?id=b384a6a8-b7a3-47ba-896b-c225296951d1">질환에 대해 더 알아보기</a></dd>
</dl>
한국당원병환우회는 국내 당원병(글리코젠축적병) 환자와 보호자를 돕는 비영리 단체로, 2023년에 설립되었어요.
2004년 다음 카페로 시작되어 2023년 정식 출범하였으며, 당원병 환우들의 건강과 행복을 목표로 다양한 활동을 합니다.
주요 활동은 당원병에 대한 인지도 개선 활동과 환우 가족들 지원, 당원병 전문 의료진 양성을 위한 활동 등으로 나뉩니다.

한국당원병환우회

공식 홈페이지

네이버 카페

질환 리포트 발행 완료

근육장애인들이 차별 받지 않고 선택권과 결정권을 온전히 누려 주체적인 삶을 살 수 있도록 당사자와 가족들을 위한 다양한 사업과 정책을 만들어가고 있습니다.

<dl class="v3-editor-content-dictionary">
<dt>신경근육질환이란</dt>
<dd>신경근육질환은 우리에게 다소 생소한 병이지만 UN이 지정한 5대 희귀난치성 질환입니다. 평범한 일상생활을 하던 사람이 어느 날 걷기, 일어나기, 달리기 등 신체 근력 기능이 떨어지기 시작하며 일상생활에 장애를 갖게 됩니다. 전신에 걸쳐 근육세포의 파괴로 인하여 점차 타인의 도움이 필요해집니다.</dd>
<dd> </dd>
<dd><a href="rarenote://MedicalNewsDetail?id=e45b16ab-b3c8-484b-84ad-4e8906229a80">질환에 대해 더 알아보기</a></dd>
</dl>
 
한국근육장애인협회는 국내 진행성 신경근육계질환 환자를 돕는 비영리 단체로, 2004년에 설립되었어요. 
주요 활동은 크게 상담지원, 프로그램 지원, 정책지원, 생활지원, 의료지원 등으로 나뉩니다. 
상담지원에는 가족상담 지원, 근육장애인 동료 상담 지원 등이, 프로그램 지원에는 여름캠프, 연말 송년 프로그램 등이 포함됩니다. 정책지원의 일환으로는 희귀질환 단체간 연합 정책 요구활동, 장애인 관련 정책 발굴 활동이 포함되며, 생활 및 의료지원을 통해 일상생활속 근육장애인에게 필요한 보조기기 및 긴급의료비 등을 지원합니다.

임상시험 현황

펜슬빔 양성자 치료기

펜슬 빔 스캐닝 양성자 치료

파트 A: OSE-279 100mg, 파트 A: OSE-279 300mg, 파트 A: OSE-279 600mg, 파트 B: OSE-279 600mg 및 OSE2101, 파트 C: OSE-279 600mg 및 OSE2101 - HLA-A2 양성, 파트 C: OSE-279 600mg - HLA-A2 양성, 파트 C: OSE-279 600mg - HLA-A2 음성

실험적(캐나다 보건부 승인 양성자 펌프 억제제)

환자 모임 정보